SLAMF7 and plasma cell myeloma: While TNFRSF17 (BCMA) was highly specific for myeloma samples, other immunotherapy targets such as CD38, CD138 (SDC1) and SLAMF7 were not or only moderately higher expressed in MM versus healthy plasma cells.